Loading
LRP1B (Low-density lipoprotein receptor-related protein 1B) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Prostate cancer, Pancreatic ductal adenocarcinoma and 5 more.
Potential cell surface proteins that bind and internalise ligands in the process of receptor-mediated endocytosis.
CIViC holds 4 clinical evidence items and 0 assertions across 4 variants, naming Immune Checkpoint Inhibitor and Doxorubicin. Open Targets scores its association with cancer at 0.77 (direct and indirect evidence; datatypes literature 0.97, affected pathway 0.76, genetic association 0.44, somatic mutation 0.88). IntOGen calls it a driver in 70 cohorts (39 activating, 27 loss-of-function), covering Acute Myeloid Leukaemia, Basal Cell Carcinoma, Invasive Breast Carcinoma, Renal Clear Cell Carcinoma, Cholangiocarcinoma, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma and others.
In plain words · LRP1B (Low-density lipoprotein receptor-related protein 1B) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Prostate cancer, Pancreatic ductal adenocarcinoma and 5 more.
LRP1B (Low-density lipoprotein receptor-related protein 1B) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Prostate cancer, Pancreatic ductal adenocarcinoma and 5 more.
Potential cell surface proteins that bind and internalise ligands in the process of receptor-mediated endocytosis. Location: Membrane (UniProt).
No product in this corpus aims at LRP1B yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA LRP1B: RNA tissue enhanced (brain 9 nTPM, thyroid gland 5 nTPM); no normal tissue stained high; highest cancer staining liver cancer (5 of 11 high). Distribution: 8 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lung cancer (all types), Prostate cancer, Pancreatic ductal adenocarcinoma, Skin cancer (all types), Oesophageal cancer, Breast cancer (all types), Colorectal cancer and more); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt Q9NZR2; CIViC gene LRP1B; IntOGen LRP1B; Human Protein Atlas LRP1B tissue; Open Targets ENSG00000168702 associations
First described 2000. Earliest sequence paper UniProt cites for the protein: Liu C.-X. et al, Cancer Res, 2000, "LRP-DIT, a putative endocytic receptor gene, is frequently inactivated in non-small cell lung cancer cell lines". Source.
Sources: HGNC HGNC:6693 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9NZR2 (protein name, function text, keywords and locations (REST API)); CIViC gene LRP1B (4 evidence items, 0 assertions, 4 variants; diseases: Glioblastoma, Ovarian Cancer, Lung Adenocarcinoma, Solid Tumour (GraphQL API, CC0)); Open Targets ENSG00000168702 (association with cancer (MONDO_0004992) 0.77; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.62, gastric cancer 0.55, oesophageal cancer 0.53, prostate cancer 0.56, ovarian cancer 0.55, melanoma 0.66 (GraphQL API, CC0)); IntOGen LRP1B (driver in 70 cohorts (Act 39, LoF 27); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Potential cell surface proteins that bind and internalise ligands in the process of receptor-mediated endocytosis. Location: Membrane (UniProt). Locus 2q22.1-q22.2 (HGNC).
RNA: tissue enhanced (brain 9 nTPM, thyroid gland 5 nTPM), detected in some normal tissues.
No normal tissue stained high; medium in Caudate, Cerebral cortex, Thyroid gland.
RNA cancer enhanced: Glioblastoma Multiforme 6 pTPM.
Medium only: cervical cancer, colorectal cancer, ovarian cancer, pancreatic cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"LRP1B" OR ABSTRACT:"LRP1B" OR TITLE:"LDL receptor related protein 1B" OR ABSTRACT:"LDL receptor related protein 1B" OR TITLE:"Low-density lipoprotein receptor-related protein 1B" OR ABSTRACT:"Low-density lipoprotein receptor-related protein 1B" OR TITLE:"LRP-DIT" OR ABSTRACT:"LRP-DIT" OR TITLE:"LRPDIT" OR ABSTRACT:"LRPDIT") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about LRP1B, not a curated reading list.